Lauren C Pinter-Brown

Title(s)Health Sciences Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Alopecia areata-like presentations with mogamulizumab therapy. JAAD Case Rep. 2023 Nov; 41:71-74. Kincaid CM, Sharma AN, Lee BA, Pinter-Brown LC, Smith J, Linden K, Mesinkovska NA. PMID: 37877094; PMCID: PMC10590718.
      View in: PubMed   Mentions:
    2. SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL. Clin Lymphoma Myeloma Leuk. 2023 06; 23(6):401-409. Brazel D, Pinter-Brown L. PMID: 37061415.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey. J Eur Acad Dermatol Venereol. 2023 Apr; 37(4):680-688. Quaglino P, Scarisbrick J, Roccuzzo G, Abeldano A, Battistella M, McCormack C, Cowan R, Cozzio A, Cury-Martins J, Enz P, Geskin L, Guenova E, Kim YH, Knobler R, Litvinov IV, Miyagaki T, Molgo M, Nicolay J, Papadavid E, Pinter-Brown L, Pujol Vallverdu R, Querfeld C, Ortiz-Romero P, Stadler R, Vermeer MH, Bagot M, Hodak E. PMID: 36606565.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Advances in the classification and management of patients with T-cell lymphoma. Clin Adv Hematol Oncol. 2022 10; 20(10):591-593. Pinter-Brown LC. PMID: 36206069.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022 08 04; 140(5):419-437. Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. PMID: 34758074; PMCID: PMC9353153.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    6. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):e947-e957. Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. PMID: 35858904.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing. Leuk Lymphoma. 2022 10; 63(10):2479-2483. Evans MG, Shestakova A, Haghighi N, Zhao X, Nardi V, Pinter-Brown LC, Rezk SA. PMID: 35503707.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. JAK/STAT: a pathway through the maze of PTCL? Blood. 2021 12 30; 138(26):2747-2748. Pinter-Brown LC. PMID: 34967872.
      View in: PubMed   Mentions: 1     Fields:    
    9. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 12 14; 5(23):5098-5106. Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. PMID: 34507350; PMCID: PMC9153035.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    10. Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):e300-e309. Bennani NN, Tun AM, Carson KR, Geiger JL, Maeda LS, Savage KJ, Rose J, Pinter-Brown L, Lunning MA, Abramson JS, Bartlett NL, Vose JM, Evens AM, Smith SM, Horwitz SM, Ansell SM, Advani RH. PMID: 34848181.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):e250-e260. Bennani NN, Tun AM, Carson KR, Geiger JL, Maeda LS, Savage KJ, Rose J, Pinter-Brown L, Lunning MA, Abramson JS, Bartlett NL, Vose JM, Evens AM, Smith SM, Horwitz SM, Ansell SM, Advani RH. PMID: 34794912; PMCID: PMC8977231.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Aggressive CD5-Positive Primary Bone Marrow Diffuse Large B-Cell Lymphoma with Leukemic Presentation. Case Rep Hematol. 2021; 2021:2628100. Evans MG, Rezk SA, Pinter-Brown LC, Zhao X. PMID: 34691792; PMCID: PMC8531795.
      View in: PubMed   Mentions: 1  
    13. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. J Eur Acad Dermatol Venereol. 2021 Nov; 35(11):2225-2238. Cowan RA, Scarisbrick JJ, Zinzani PL, Nicolay JP, Sokol L, Pinter-Brown L, Quaglino P, Iversen L, Dummer R, Musiek A, Foss F, Ito T, Rosen JP, Medley MC. PMID: 34273208; PMCID: PMC9290719.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    14. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. Eur J Cancer. 2021 05; 148:411-421. Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R. PMID: 33794441; PMCID: PMC9347228.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    15. Strategies for aggressive T-cell lymphoma: divide and conquer. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):154-159. Pinter-Brown LC. PMID: 33275729; PMCID: PMC7727519.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin Cancer Res. 2021 02 15; 27(4):1139-1149. Anastasiadou E, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L, Marchese C, Avigan D, Trivedi P, Escolar DM, Jackson AL, Slack FJ. PMID: 33208342; PMCID: PMC8287597.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    17. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection. Drug Des Devel Ther. 2020; 14:3747-3754. Blackmon AL, Pinter-Brown L. PMID: 32982179; PMCID: PMC7502391.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    18. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel). 2020 Aug 15; 12(8). Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. PMID: 32824175; PMCID: PMC7463651.
      View in: PubMed   Mentions: 34  
    19. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer. 2020 07; 133:120-130. Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. PMID: 32502876.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    20. Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):744-748. Lansigan F, Horwitz SM, Pinter-Brown LC, Carson KR, Shustov AR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Foss FM. PMID: 32532611; PMCID: PMC8447249.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. B-cell lymphomas associated with breast implants: Report of three cases and review of the literature. Ann Diagn Pathol. 2020 Jun; 46:151512. Evans MG, Miranda RN, Young PA, Pai L, Wang HY, Konoplev SN, Medeiros LJ, Pinter-Brown LC. PMID: 32315816.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    22. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematol. 2020; 143(1):40-50. Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. PMID: 31315113.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    23. Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. Am J Hematol. 2019 06; 94(6):641-649. Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. PMID: 30896890; PMCID: PMC7928240.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    24. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019 05 01; 125(9):1507-1517. Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR, COMPLETE Investigators. PMID: 30694529; PMCID: PMC8269282.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    25. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 09; 19(9):1192-1204. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators. PMID: 30100375.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCTClinical Trials
    26. Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. Exp Hematol Oncol. 2018; 7:12. Johnston PB, Pinter-Brown LC, Warsi G, White K, Ramchandren R. PMID: 29774169; PMCID: PMC5948762.
      View in: PubMed   Mentions: 22  
    27. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018 06; 181(6):760-769. Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter-Brown LC, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH, T cell Project Network. PMID: 29672827; PMCID: PMC6033106.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    28. Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma. J Clin Pharm Ther. 2017 Dec; 42(6):776-779. Tran PN, Pinter-Brown LC. PMID: 28661568.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clin Lymphoma Myeloma Leuk. 2017 04; 17(4):193-200. Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. PMID: 28209473.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    30. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. J Natl Cancer Inst. 2017 02; 109(2). Casulo C, O'Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, Kahl BS, Little RF, Pinter-Brown L, Advani R, Horwitz S. PMID: 28040682; PMCID: PMC6059211.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    31. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017 Apr 01; 123(7):1174-1183. Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. PMID: 27911989; PMCID: PMC5650190.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    32. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2016 07 20; 34(21):2484-92. Crump M, Leppä S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T. PMID: 27217449.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    33. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016 Feb; 172(4):535-44. Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM. PMID: 26627450; PMCID: PMC5642048.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    34. Diagnosis and Management of Cutaneous B-cell Lymphoma. Dermatol Clin. 2015 Oct; 33(4):835-40. Pinter-Brown LC. PMID: 26433853.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    35. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015 Mar; 135(3):695-705. Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, Carlson G, Lechner MG, Epstein AL. PMID: 25490535.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    36. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar 19; 125(12):1883-9. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. PMID: 25605368; PMCID: PMC4375715.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    37. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Apr; 26(4):774-779. Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. PMID: 25605745; PMCID: PMC4374388.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    38. A case of mycosis fungoides transmitted from donor to recipient, and review of literature of T-cell malignancies after transplantation. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):e137-40. Loh JC, Cassarino DS, Grody WW, Chiu MW, Pinter-Brown LC. PMID: 24637131.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    39. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan 23; 7:11. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. PMID: 24456586; PMCID: PMC4016573.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    40. Acral lymphomatoid papulosis associated with poikilodermatous mycosis fungoides. Dermatol Online J. 2013 Feb 15; 19(2):1. Magorien J, Hillman JD, Pinter-Brown LC, Said J, Chiu MW. PMID: 23473271.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):238-43. Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. PMID: 22542448.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    42. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012 Apr 19; 119(16):3698-704. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, DiRienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A, 405 Study Investigators. PMID: 22389254.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCellsCTClinical Trials
    43. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20; 30(6):631-6. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. PMID: 22271479.
      View in: PubMed   Mentions: 236     Fields:    Translation:HumansCTClinical Trials
    44. Discussion: A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg. 2011 Sep; 128(3):122e-123e. Pinter-Brown LC. PMID: 21865984.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma. 2011 Aug; 52(8):1474-80. Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. PMID: 21649541.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    46. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011 Jun 20; 29(18):2598-607. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC, International Society for Cutaneous Lymphomas, United States Cutaneous Lymphoma Consortium, Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. PMID: 21576639; PMCID: PMC3422534.
      View in: PubMed   Mentions: 189     Fields:    Translation:Humans
    47. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20; 29(9):1182-9. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. PMID: 21245435; PMCID: PMC3083873.
      View in: PubMed   Mentions: 214     Fields:    Translation:HumansCTClinical Trials
    48. Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant. 2011 Sep; 46(9):1219-25. Andorsky DJ, Cohen M, Naeim A, Pinter-Brown L. PMID: 21151188.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    49. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011 Feb; 64(2):352-404. Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. PMID: 21145619.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    50. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol. 2010 Dec; 63(6):975-83. Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. PMID: 20888065.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    51. Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J. 2010 Jul 15; 16(7):1. Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu MW. PMID: 20673529.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion. Clin Adv Hematol Oncol. 2009 Nov; 7(11):S1, S4-13; quiz S15. Said J, Pinter-Brown L. PMID: 20095101.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    53. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009 Oct 01; 15(19):6217-24. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. PMID: 19789316.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    54. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009 Jul; 146(2):171-9. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK. PMID: 19466965.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    55. Intraocular involvement of mycosis fungoides. Arch Ophthalmol. 2009 Mar; 127(3):343-5. Ralli M, Goldman JW, Lee E, Pinter-Brown LC, Glasgow BJ, Sarraf D. PMID: 19273807.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    56. SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies. Expert Opin Investig Drugs. 2008 Dec; 17(12):1883-7. Pinter-Brown LC. PMID: 19012503.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    57. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007 Feb; 56(2):317-26. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. PMID: 17141360.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    58. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006 Jun; 91(6):2205-8. Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. PMID: 16595600.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma. 2004 Jun; 5(1):45-9. Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P. PMID: 15245607.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    60. Regression of cutaneous intravascular lymphoma with rituximab. Cutis. 2003 Aug; 72(2):137-40. Han K, Haley JC, Carlson K, Pinter-Brown L, Soriano T. PMID: 12953938.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod Pathol. 2003 Jun; 16(6):543-51. Roberts AA, Amano M, Felten C, Galvan M, Sulur G, Pinter-Brown L, Dobbeling U, Burg G, Said J, Baum LG. PMID: 12808059.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    62. Immunogenetic analysis of bone marrow aspirates in patients with non-Hodgkin lymphomas. Am J Hematol. 1990 Mar; 33(3):160-6. Ellison DJ, Hu E, Zovich D, Pinter-Brown L, Pattengale PK. PMID: 2154093.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    63. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer. 1990 Feb 15; 65(4):878-84. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. PMID: 2297658.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    64. Third-World Hodgkin's disease at Los Angeles County-University of Southern California Medical Center. J Clin Oncol. 1988 Aug; 6(8):1285-92. Hu E, Hufford S, Lukes R, Bernstein-Singer M, Sobel G, Gill P, Pinter-Brown L, Rarick M, Rosen P, Brynes R, et al. PMID: 3411341.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Lauren's Networks
    Concepts (233)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (27)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California